TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01853917

Intervention type: OTHER
Intervention: questionaires and structured interviews
Description: We will do questionaires on pregnant women before they have their baby and after they have their baby. We will do structured interviews after they have their baby
Study: NCT03378765

Intervention type: BEHAVIORAL
Intervention: Diet and physical activity monitoring
Description: Lifestyle monitoring
Study: NCT03323840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentivized Care
Description: Patients will receive a $10 gift card for every blood pressure measurement (up to 2 times/month)
Study: NCT03153111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macitentan
Description: macitentan 10 mg; film-coated tablet; oral use
Study: NCT02040844

Intervention type: DRUG
Group type: OTHER
Intervention: Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762]

Intervention type: DRUG
Group type: OTHER
Intervention: Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762]

Intervention type: DRUG
Group type: OTHER
Intervention: Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]
Study: NCT02214251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PK-16CH EXG system
Study: NCT00946192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal 17Beta-estradiol, progesterone
Description: 100 mcg/day 17Beta-estradiol; transdermal twice weekly application for 12 months (with cyclic micronized progesterone pills (Prometrium): 200 mg taken orally daily Day 1 to Day 12 each month) + Elemental calcium 1200 mg and Vit D 400 IU taken orally daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinyl Estradiol + Desogestrel
Description: Oral ethinyl estradiol (0.03 mg) + desogestrel (0.15 mg) + Elemental calcium 1200 mg and Vit D 400 IU taken once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
Study: NCT00070954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ginkgo biloba
Description: EgB 761

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: matched placebo
Description: Inactive look-alike placebo
Study: NCT04244591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone therapy
Description: Methylprednisolone 40 mg q12h for 5 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Standard care
Study: NCT00186810

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan, Cyclophosphamide, Horse ATG
Description: Transplant recipients received a myeloablative conditioning regimen of cyclophosphamide, Anti-Thymocyte Globulin (horse), and Busulfan. Cyclosporine and methotrexate were administered for GVHD prophylaxis.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic stem cell transplant
Description: Allogeneic stem cell transplant Matched sibling donor transplant Cord blood transplant
Study: NCT01719536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib: 125 mg is administered orally three times per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: First-line chemotherapy: pemetrexed/cisplatin for 4 cycles. Maintenance treatment: pemetrexed.
Study: NCT04248829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib 240 mg/160 mg
Description: The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances
Study: NCT03153111

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: film-coated tablet (identical to the macitentan tablet); oral use
Study: NCT01975935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlexanox
Description: 25 mg amlexanox tablets blinded by encapsulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo sham blinded by encapsulation in the same capsules as the study drug arm
Study: NCT04248829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib 250 mg
Description: The initial dose for Gefitinib (250 mg once daily) cannot be reduced to a lower dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lazertinib-matching placebo 240 mg/160 mg
Description: The initial dose of lazertinib-matching placebo 240 mg (3 tablets of 80 mg lazertinib-matching placebo) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib-matching placebo) under specific circumstances

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib-matching placebo 250 mg
Description: The initial dose for Gefitinib-matching placebo (250 mg once daily) cannot be reduced to a lower dose
Study: NCT02549443

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino acids
Description: AA (Travasol Baxter, Deerfield IL) during and after surgery in an amount equivalent to 20% and 35% of the patient's energy expenditure (EE)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino acids
Description: AA (Travasol Baxter, Deerfield IL) during and after surgery in an amount equivalent to 20% and 35% of the patient's energy expenditure (EE)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino acids
Description: AA (Travasol Baxter, Deerfield IL) during and after surgery in an amount equivalent to 20% and 35% of the patient's energy expenditure (EE)
Study: NCT01634919

Intervention type: DEVICE
Intervention: chronic hepatitis C
Description: acoustic radiation force impulse ultrasonography
Study: NCT00968331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus Rituximab
Description: Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles. Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles.
Study: NCT03105102

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Risankizumab SC
Description: Placebo for Risankizumab SC Subcutaneous (SC) Injection
Study: NCT01728740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500mg, oral, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500mg, oral, single dose
Study: NCT06081140

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Process Hemp Oil Complex
Description: 10 days of supplementation to determine the tolerance and palatability of Standard Process Hemp Oil Complex.
Study: NCT06614023

Intervention type: PROCEDURE
Intervention: coronary artery bypass grafting
Description: surgical coronary revascularization

Intervention type: PROCEDURE
Intervention: coronary artery bypass grafting
Description: surgical coronary revascularization

Intervention type: PROCEDURE
Intervention: coronary artery bypass grafting
Description: surgical coronary revascularization

Intervention type: PROCEDURE
Intervention: coronary artery bypass grafting
Description: surgical coronary revascularization

Intervention type: PROCEDURE
Intervention: coronary artery bypass grafting
Description: surgical coronary revascularization

Intervention type: PROCEDURE
Intervention: coronary artery bypass grafting
Description: surgical coronary revascularization
Study: NCT06614374

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-dose fish oil capsules
Description: Patients in the low-dose group will receive four fish-oil and refined olive oil mixed capsules containing 1.5 g of marine n-3 PUFAs per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-dose fish oil capsules
Description: Patients in the high-dose group will receive four fish oil capsules containing 3 g of marine n-3 PUFAs (72% EPA and 28% DHA) per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Refined olive oil
Description: Participants in the control group will receive 4 g refined olive oil daily
Study: NCT03397914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistimethate Sodium
Description: Intravenous injection of colistimethate Sodium 2.5 mg/kg or 5 mg/kg for Multidrug-resistance gram negative infections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistimethate Sodium
Description: Intravenous injection of colistimethate Sodium 2.5 mg/kg or 5 mg/kg for Multidrug-resistance gram negative infections
Study: NCT04223284

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: D-Limonene
Description: Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% D-Limonene in the nose for 15 minutes
Study: NCT03484182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Home Exercise Program
Description: Home exercises that are guided by a web-based program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Home Exercise Program
Description: Standard paper-based home exercise program
Study: NCT03105102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Risankizumab SC
Description: Placebo for Risankizumab SC Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab IV
Description: Risankizumab IV Intravenous (IV) infusion
Study: NCT04223284

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: D-Limonene
Description: Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% D-Limonene in the nose for 15 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SLVO
Description: Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% SLVO in the nose for 15 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SLVO
Description: Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% SLVO in the nose for 15 minutes
Study: NCT03105102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Risankizumab IV
Description: Placebo for Risankizumab IV Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab SC
Description: Risankizumab SC Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab SC
Description: Risankizumab SC Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab SC
Description: Risankizumab SC Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab SC
Description: Risankizumab SC Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab SC
Description: Risankizumab SC Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab SC
Description: Risankizumab SC Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab SC
Description: Risankizumab SC Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab On-Body Injector (OBI)
Description: Subcutaneous (SC) injection; on-body injector (OBI)
Study: NCT02042404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sound amplification provided via EarLens System.
Description: The EarLens System has two primary components: 1) an external Behind the Ear (BTE) Sound Processing Unit, and 2) a Tympanic Membrane Transducer (TM Transducer). In this system, light is used to wirelessly transmit both signal and power from the BTE Sound Processor to the TM Transducer. The BTE is designed to be able to be removed, reprogrammed, and have the battery recharged as needed, similar to a BTE for an air conduction hearing aid. The removable TM Transducer is customized for each patient, is placed and removed by a physician in an office visit procedure, and is designed to reside in the ear in a safe and stable manner for long periods of time.
Study: NCT04138004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol in combination with lubiprostone
Description: 2-litre polyethylene glycol split-dose in combination with one 24 mcg tablet of lubiprostone
Study: NCT02996695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Artesunate is a succinic ester of artemether.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artesunate
Description: Artesunate is a succinic ester of artemether.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: 4-aminoquinolone, antimalarial agent for oral administration
Study: NCT04138004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol alone
Description: 4-litre polyethylene glycol split-dose
Study: NCT02996695

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chloroquine
Description: 4-aminoquinolone, antimalarial agent for oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ (NF54) Challenge
Description: Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ (NF54) Challenge
Description: Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.
Study: NCT03761667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoscopy using Narrow band imaging
Description: Inspection of resection margin of SSA/P for the evaluation of complete resection or the presence of remnant lesion using NBI method
Study: NCT00369122

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT04167384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual brand (UB) filtered, combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual brand (UB) filtered, combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Nicorette® Mint 4 mg nicotine lozenge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Nicorette® Mint 4 mg nicotine lozenge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: CSD1903-11, a hard nicotine lozenge, 2 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: CSD1903-11, a hard nicotine lozenge, 4 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: CSD1903-11, a hard nicotine lozenge, 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product F
Description: CSD1903-12, a soft nicotine lozenge, 2 mg nicotine
Study: NCT00369122

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo brachytherapy
Study: NCT01072669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ambrisentan
Description: Subjects will receive ambrisentan 5 mg orally once daily or identical placebo pills for the first 4 weeks and then increased to ambrisentan 10mg once daily\[if the lower dose is tolerated\] or identical placebo pills for the rest of the study. They will be instructed to take the 5mg/pink pills for 4 weeks and then switch to 10mg /red pills unless they are having any drug related side effects or concerns. There will be no routine visit planned at 4 weeks to assess drug tolerance unless a complication arises. Adherence to treatment will be assessed by pill counting at each follow up visit. Follow up digital blood flow measurements will be obtained with LDPI at 1 week and at 3 months, where the same protocol (as that in the initial visit) will be followed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ambrisentan
Description: Subjects will receive ambrisentan 5 mg orally once daily or identical placebo pills for the first 4 weeks and then increased to ambrisentan 10mg once daily\[if the lower dose is tolerated\] or identical placebo pills for the rest of the study. They will be instructed to take the 5mg/pink pills for 4 weeks and then switch to 10mg /red pills unless they are having any drug related side effects or concerns. There will be no routine visit planned at 4 weeks to assess drug tolerance unless a complication arises. Adherence to treatment will be assessed by pill counting at each follow up visit. Follow up digital blood flow measurements will be obtained with LDPI at 1 week and at 3 months, where the same protocol (as that in the initial visit) will be followed.
Study: NCT04167384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: CSD1903-12, a soft nicotine lozenge, 4 mg nicotine
Study: NCT00808678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-143
Description: once, see arm description for more information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335
Description: once, see arm description for more information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Description: once, see arm description for more detail
Study: NCT04167384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product H
Description: CSD1903-12, a soft nicotine lozenge, 8 mg nicotine
Study: NCT02102932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg empagliflozin/850 mg metformin FDC
Description: 5 mg empagliflozin/850 mg metformin FDC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12.5 mg empagliflozin
Description: 10 mg empagliflozin tablet and 2.5 mg empagliflozin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12.5 mg empagliflozin
Description: 10mg empagliflozin tablet and 2.5 mg empagliflozin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 850 mg metformin
Description: 850mg metformin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg empagliflozin
Description: 5 mg empagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg empagliflozin
Description: 5 mg empagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 850 mg metformin
Description: 850 mg metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12.5 mg empagliflozin/850 mg metformin FDC
Description: 12.5 mg empagliflozin/850 mg metformin FDC
Study: NCT04171765

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive subcutaneous (SC) placebo matched to BFKB8488A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFKB8488A
Description: Participants will receive subcutaneous (SC) BFKB8488A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFKB8488A
Description: Participants will receive subcutaneous (SC) BFKB8488A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFKB8488A
Description: Participants will receive subcutaneous (SC) BFKB8488A.
Study: NCT01341197

Intervention type: OTHER
Intervention: Fecal immunochemical test, guaiac fecal occult-blood test, and Helicobacter pylori stool antigen test

Intervention type: OTHER
Intervention: Fecal immunochemical test, guaiac fecal occult-blood test, and Helicobacter pylori stool antigen test
Study: NCT02224092

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: multivitamin multimineral with phytonutrient supplementation
Description: The multivitamin multimineral with phytonutrient product consists of four tablets per dose, two Vitamin tablets, a Mineral tablet, and a Phytonutrient tablet. The placebo for this trial will be formulated to match the shape and color of all multivitamin multimineral with phytonutrient product tablets, e.g., a Vitamin Placebo, a Mineral Placebo and a Phytonutrient Placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: multivitamin multimineral with phytonutrient supplementation
Description: The multivitamin multimineral with phytonutrient product consists of four tablets per dose, two Vitamin tablets, a Mineral tablet, and a Phytonutrient tablet. The placebo for this trial will be formulated to match the shape and color of all multivitamin multimineral with phytonutrient product tablets, e.g., a Vitamin Placebo, a Mineral Placebo and a Phytonutrient Placebo.
Study: NCT03595774

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beet root juice
Description: Beet root juice

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beet root juice
Description: Beet root juice

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beet root juice
Description: Beet root juice
Study: NCT04558580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rufinamide
Description: Rufinamide
Study: NCT04612582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Bortezomib (d 1, 8, 15, 22, 1.3mg /m2, subcutaneous injection); thalidomide (d 1-28 50-100mg, oral); dexamethason (d 1, 2, 8, 9, 15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, the patients will complete six courses of treatment after entering the group, and the total observation time is one year after the end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Bortezomib (d 1, 8, 15, 22,1.3mg / m2, subcutaneous injection); cyclophosphamide (d 1, 2,900mg / m2, intravenous drip); dexamethason (d 1, 2, 8, 9,15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, patients will complete six courses of treatment after entering the group, the overall observation time is one year after the end of treatment.
Study: NCT01385761

Intervention type: DEVICE
Intervention: Laryngeal Mask Airway
Description: Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.

Intervention type: DEVICE
Intervention: air-QTM Intubating Laryngeal Airway
Description: Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.